Dose reduction of risperidone and olanzapine can improve cognitive function and negative symptoms in stable schizophrenic patients: A single-blinded, 52-week, randomized controlled study

Optimal Dosing of Risperidone and Olanzapine in the Maintenance Treatment for Patients With Schizophrenia and Related Psychotic Disorders

(2017) Yusaku Yoshimura et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Prescription Practices in the Treatment of First-Episode Schizophrenia Spectrum Disorders: Data From the National RAISE-ETP Study

(2015) Delbert G. Robinson et al.   AMERICAN JOURNAL OF PSYCHIATRY

Antipsychotic polypharmacy in schizophrenia patients in China and its association with treatment satisfaction and quality of life: Findings of the third national survey on use of psychotropic medications in China

(2014) Qian Li et al.   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

Antipsychotic Treatment and Mortality in Schizophrenia

(2014) M. Torniainen et al.   SCHIZOPHRENIA BULLETIN

Effects of Risperidone and Olanzapine Dose Reduction on Cognitive Function in Stable Patients With Schizophrenia: An Open-Label, Randomized, Controlled, Pilot Study

(2013) H. Takeuchi et al.   SCHIZOPHRENIA BULLETIN

Recovery in Remitted First-Episode Psychosis at 7 Years of Follow-up of an Early Dose Reduction/Discontinuation or Maintenance Treatment Strategy

(2013) Lex Wunderink et al.   JAMA Psychiatry

Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: A cross-sectional study

(2012) Yuya Mizuno et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Dopamine D2 Receptor Occupancy and Cognition in Schizophrenia: Analysis of the CATIE Data

(2012) Hitoshi Sakurai et al.   SCHIZOPHRENIA BULLETIN

Long-term Antipsychotic Treatment and Brain Volumes

(2011) Beng-Choon Ho et al.   ARCHIVES OF GENERAL PSYCHIATRY

Dopamine D2 Receptor Occupancy and Clinical Effects

(2011) Hiroyuki Uchida et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology

(2011) Thomas RE Barnes et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Processing Speed Deficits in Schizophrenia: Reexamining the Evidence

(2010) Emma E.M. Knowles et al.   AMERICAN JOURNAL OF PSYCHIATRY

D2 Receptor Blockade by Risperidone Correlates With Attention Deficits in Late-Life Schizophrenia

(2009) Hiroyuki Uchida et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Cognitive effects of antipsychotic dosage and polypharmacy: a study with the BACS in patients with schizophrenia and schizoaffective disorder

(2009) D. Élie et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Low Dose vs Standard Dose of Antipsychotics for Relapse Prevention in Schizophrenia: Meta-analysis

(2009) Hiroyuki Uchida et al.   SCHIZOPHRENIA BULLETIN

The 2009 Schizophrenia PORT Psychosocial Treatment Recommendations and Summary Statements

(2009) L. B. Dixon et al.   SCHIZOPHRENIA BULLETIN

The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009

(2009) Julie Kreyenbuhl et al.   SCHIZOPHRENIA BULLETIN

The MATRICS Consensus Cognitive Battery, Part 1: Test Selection, Reliability, and Validity

(2008) Keith H. Nuechterlein et al.   AMERICAN JOURNAL OF PSYCHIATRY

High-dose antipsychotic use in schizophrenia: a comparison between the 2001 and 2004 Research on East Asia Psychotropic Prescription (REAP) studies

(2008) Kang Sim et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Strategies of treatment with olanzapine in schizophrenic patients during stable phase: Results of a pilot study

(2008) Frédéric Rouillon et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY